![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the...
On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to...
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.07 | -5.51181102362 | 1.27 | 1.27 | 1.11 | 315498 | 1.17799178 | CS |
4 | -0.52 | -30.2325581395 | 1.72 | 1.73 | 1.11 | 322979 | 1.33900037 | CS |
12 | -1.04 | -46.4285714286 | 2.24 | 2.43 | 1.11 | 283942 | 1.69633988 | CS |
26 | -1.22 | -50.4132231405 | 2.42 | 3.1399 | 1.11 | 281251 | 1.93850403 | CS |
52 | -3.95 | -76.6990291262 | 5.15 | 5.15 | 1.11 | 221323 | 2.31593443 | CS |
156 | -19.65 | -94.2446043165 | 20.85 | 23.535 | 1.11 | 158829 | 5.54644657 | CS |
260 | -40.82 | -97.1442170395 | 42.02 | 63.62 | 1.11 | 164840 | 9.95897609 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions